問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊景堯

Recruiting

List

193Cases

2020-06-01 - 2024-05-31

Phase I

Completed
A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL-15/sIL-15Rα)) in Combination With Spartalizumab in Patients With Check Point Inhibitor (CPI) Relapsed Advanced Solid Tumors and Lymphoma

  • Condition/Disease

    Advanced Solid Tumors and Lymphoma

  • Test Drug

    NIZ985PDR001

Participate Sites
1Sites

Recruiting1Sites

2020-10-15 - 2026-12-31

Phase II

Active
Phase 2, Multicenter, Randomized Study of DS-1062a in Advanced or Metastatic Non-Small Cell Lung Cancer with Actionable Genomic Alterations and Previously Treated with Kinase Inhibitor Therapy and Platinum-based Chemotherapy with or without Prior Immunotherapy

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    DS-1062a

Participate Sites
4Sites

Recruiting4Sites

2024-01-15 - 2029-12-31

Phase III

Active
Beamion LUNG-2: A Phase III, open-label, randomized, active- controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non- squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

  • Condition/Disease

    unresectable, locally advanced or metastatic non- squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

  • Test Drug

    Zongertinib

Participate Sites
5Sites

Recruiting5Sites

2022-11-15 - 2034-07-12

Others

xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    AlectinibEntrectinibEntrectinibPralsetinibDurvalumab

Participate Sites
8Sites

Recruiting8Sites

2022-06-01 - 2026-06-30

Phase II

A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)

  • Condition/Disease

    Extensive-stage Small-cell Lung Cancer

  • Test Drug

    Ifinatamab Deruxtecan (I-DXd)

Participate Sites
6Sites

Recruiting6Sites

2024-08-01 - 2028-03-31

Phase II

A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA)

  • Condition/Disease

    Lung Cancer

  • Test Drug

    Osimertinib tablets 40 mg

Participate Sites
7Sites

Recruiting7Sites

2023-07-01 - 2030-06-30

Phase II/III

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

  • Condition/Disease

    Advanced Non-Small Cell Lung Cancer

  • Test Drug

    REGN3767 (Fianlimab) REGN2810 (Cemiplimab)

Participate Sites
8Sites

Recruiting8Sites

2024-01-01 - 2030-12-31

Phase III

SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression

  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    Carboplatin|Cisplatin|LY3537982|Pembrolizumab|Pemetrexed|Placebo

Participate Sites
14Sites

Recruiting14Sites

2020-07-01 - 2022-01-17

Phase I

A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid Tumors

  • Condition/Disease

    Malignant Solid Tumor

  • Test Drug

    SAR439459

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2022-01-01 - 2025-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 13 14 15 16 17 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB